New therapies, such as IL-17 inhibitors (Secukinumab, ixekizumab) and IL-23 inhibitors (Risankizumab, guselkumab), are emerging as potential treatments for PRP [4]. Here, IL37 is linked to familial pityriasis rubra pilaris.